TENUATE DOSPAN (diethylpropion hydrochloride) by ANI Pharmaceuticals is clinical pharmacology diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity, higher. First approved in 1960.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
TENUATE DOSPAN (diethylpropion hydrochloride) is a sympathomimetic amine anorectic agent approved in 1960 for the management of exogenous obesity. It works through central nervous system stimulation and appetite suppression, though the exact mechanism of weight loss is not fully established. The extended-release 75 mg tablet formulation provides once-daily dosing with gradual drug release.
Product is approaching loss of exclusivity with stable but declining market presence; expect rightsizing of brand and managed care teams.
CLINICAL PHARMACOLOGY Diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Actions include some central nervous system stimulation and elevation of blood pressure. Tolerance…
Worked on TENUATE DOSPAN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TENUATE DOSPAN offers limited career advancement potential given its LOE-approaching status and lack of clinical development. Roles are primarily defensive and focused on market maintenance rather than growth, making this a terminal assignment for most career paths.